Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Total Non-Current Liabilities: 2011-2024

Historic Total Non-Current Liabilities for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $139.3 million.

  • Adma Biologics' Total Non-Current Liabilities fell 13.22% to $137.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.4 million, marking a year-over-year decrease of 13.22%. This contributed to the annual value of $139.3 million for FY2024, which is 28.03% down from last year.
  • As of FY2024, Adma Biologics' Total Non-Current Liabilities stood at $139.3 million, which was down 28.03% from $193.6 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Total Non-Current Liabilities ranged from a high of $196.1 million in FY2022 and a low of $119.4 million during FY2020.
  • Over the past 3 years, Adma Biologics' median Total Non-Current Liabilities value was $193.6 million (recorded in 2023), while the average stood at $176.3 million.
  • Per our database at Business Quant, Adma Biologics' Total Non-Current Liabilities skyrocketed by 45.63% in 2022 and then declined by 28.03% in 2024.
  • Adma Biologics' Total Non-Current Liabilities (Yearly) stood at $119.4 million in 2020, then climbed by 12.83% to $134.7 million in 2021, then skyrocketed by 45.63% to $196.1 million in 2022, then declined by 1.32% to $193.6 million in 2023, then fell by 28.03% to $139.3 million in 2024.